Amylyx's ALS drug fails in late-stage confirmatory study-March 2024-www.financetom.com

Amylyx's ALS drug fails in late-stage confirmatory study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Amylyx's ALS drug fails in late-stage confirmatory study

Mar 8, 2024 4:24 AM

March 8 (Reuters) - Amylyx Pharmaceuticals ( AMLX )

said on Friday its drug to treat a neurological disorder called

ALS, or amyotrophic lateral sclerosis, failed to meet the main

goal in a late-stage confirmatory study.

The company said its plans for the drug may include

voluntarily withdrawing it from the market.

(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj

Kalluvila)

Previous page： NHTSA launches engineering analysis into nearly 1 mln Stellantis Dodge SUVs Next page： Deals of the day-Mergers and acquisitions

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NHTSA launches engineering analysis into nearly 1 mln Stellantis Dodge SUVs

Aug 2, 2024

Aug 2 (Reuters) - The National Highway Traffic Safety Administration on Friday upgraded its investigation into nearly 1 million Stellantis' ( STLA ) Dodge brand vehicles to an engineering analysis from a preliminary evaluation over faulty door locks and windows. The analysis involves certain Dodge Journey crossovers built between 2009 and 2020. Stellantis ( STLA ) did not immediately respond...

Deals of the day-Mergers and acquisitions

Aug 2, 2024

Aug 2 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Carlsberg has agreed to take full control of its business in India and Nepal, the Danish brewer said. ** Switzerland's Sika AG said it had acquired chemicals construction company Vinaldom in the Dominican Republic, boosting the firm's presence in the Caribbean....

NHTSA launches engineering analysis into nearly 1 million Stellantis Dodge SUVs

Aug 2, 2024

(Reuters) -The National Highway Traffic Safety Administration on Friday upgraded its investigation into nearly 1 million Stellantis' ( STLA ) Dodge brand vehicles to an engineering analysis from a preliminary evaluation over faulty door locks and windows. The analysis involves certain Dodge Journey crossovers built between 2009 and 2020. Stellantis ( STLA ) did not immediately respond to a Reuters...

Arcosa's Q2 Adjusted Earnings, Revenue Increase; Company to Acquire Construction Materials Business of Stavola

Aug 2, 2024

05:47 AM EDT, 08/02/2024 (MT Newswires) -- Arcosa ( ACA ) reported Q2 adjusted earnings Thursday of $0.91 per diluted share, up from $0.76 a year earlier. Analysts polled by Capital IQ expected $0.83. Revenue for the quarter ended June 30 was $664.7 million, compared with $584.8 million a year earlier. Analysts polled by Capital IQ expected $661.5 million. The...